Finvest
MRNA Biotechnology · Biotech · Vaccines · mRNA platform · Thesis updated July 12, 2026

Moderna still needs proof beyond COVID

01 Running thesis

A platform under pressure

Moderna is trying to turn its COVID windfall into a lasting biotech business. The bull case is simple: the mRNA platform keeps producing real products, and the company now has four approved vaccines. Q1 2026 added more evidence, with revenue of $389 million and management repeating guidance for up to 10% revenue growth in 2026.

The newest win is mCOMBRIAX, a flu and COVID combo vaccine approved in Europe for people 50 and older. If it gains use during the 2026 and 2027 respiratory season, Moderna can show that its platform can sell more than stand-alone COVID shots.

The bear case is still hard to ignore. Moderna lost $1.3 billion in Q1 2026, helped by a $950 million Arbutus and Genevant settlement that is payable in Q3 2026. For full-year 2025, revenue fell to $1.9 billion from $3.2 billion, and the RSV vaccine added only $8 million of product sales.

The next year is mostly about proof. Investors will watch the FDA decision for the seasonal flu vaccine mRNA-1010 by August 5, 2026, the European launch of mCOMBRIAX, possible FDA guidance on a U.S. combo-vaccine re-filing, melanoma data for mRNA-4157, and rare disease data for mRNA-3927.

May 2026Q1 2026 confirmed the transition story. Revenue rose to $389 million, management repeated guidance for up to 10% revenue growth in 2026, and mCOMBRIAX became Moderna's fourth approved product.
May 2026The same filing showed the cost of the transition. Moderna reported a $1.3 billion net loss, including the $950 million Arbutus and Genevant settlement payable in Q3 2026.
Feb 2026The 2025 10-K showed revenue falling to $1.9 billion from $3.2 billion and a full-year net loss of $2.8 billion. RSV sales were only $8 million, which kept commercial execution risk high.
Nov 2025The Phase 3 congenital CMV vaccine trial failed its main goal, and Moderna discontinued that program. This raised the risk around non-respiratory pipeline success.
Aug 2025mNEXSPIKE was approved, and mRESVIA received an expanded label, but Q2 revenue fell to $114 million. The BARDA pandemic flu contract termination added funding pressure.
May 2025Cost cuts and the lifted norovirus clinical hold helped the bull case. Very weak RSV sales and lower product revenue kept the bear case alive.
Feb 2025The 2024 10-K set the post-pandemic frame. COVID product sales had fallen sharply, mRESVIA sales were modest, and Moderna began targeting a $1 billion annual R&D cut by 2027.
Nov 2024Moderna reported its first RSV revenue and showed better cost discipline in Q3 2024. It also narrowed the pipeline by prioritizing higher-impact programs.
02 Business model

Selling shots while funding science

Moderna makes money by selling vaccines based on messenger RNA, or mRNA. mRNA is a set of instructions that tells cells to make a target protein, so the immune system can learn what to fight.

Today the business is still mostly a respiratory vaccine company. Its approved products are Spikevax for COVID, mNEXSPIKE as a next-generation COVID shot, mRESVIA for RSV, and mCOMBRIAX for flu plus COVID in Europe.

The model works only if new products can replace shrinking COVID demand. That is why cost control matters. In Q1 2026, R&D expense fell 24% year over year, and management guided to roughly $4.2 billion of full-year adjusted cash costs.

Moderna is also using partners where it makes sense. Its Recordati deal for mRNA-3927, a propionic acidemia therapy, lets Moderna lead clinical development while Recordati would help with global commercialization if approved.

03 Product portfolio

Four products, many bets

Cash cow

Spikevax

Spikevax is Moderna's original COVID-19 vaccine. Sales have moved from a pandemic surge to a smaller seasonal market.

Steady

mNEXSPIKE

mNEXSPIKE is the next-generation COVID vaccine launched in Q3 2025. Moderna says it became its leading U.S. retail-channel product in 2025.

Option

mRESVIA

mRESVIA is the RSV vaccine. It is approved for adults 60 and older, plus adults 18 to 59 who are at higher risk, but sales were only $8 million in 2025.

Growth engine

mCOMBRIAX

mCOMBRIAX combines flu and COVID protection in one shot. It was approved in Europe in April 2026 for people 50 and older.

Option

mRNA-1010 seasonal flu vaccine

mRNA-1010 is Moderna's stand-alone flu vaccine candidate. The FDA PDUFA goal date is August 5, 2026.

Option

mRNA-4157 cancer therapy

mRNA-4157 is an individualized cancer therapy partnered with Merck. Five-year melanoma data showed sustained improvement in recurrence-free survival, and nine Phase 2 or Phase 3 trials are underway.

Option

mRNA-3927 rare disease therapy

mRNA-3927 targets propionic acidemia, a rare disease. Its registrational study has reached target enrollment, and Recordati is Moderna's commercialization partner.

04 Business segments

Still a COVID-heavy mix

COVID vaccines100%declining
RSV vaccine0%declining

Moderna reports as one operating segment. The product-sales mix shown here is from full-year 2025 net product sales of $1.818 billion, made up of $1.810 billion from COVID vaccines and $8 million from mRESVIA.

05 Risk factors

What could break the story

New vaccines do not sell

High impact · High odds

The biggest risk is commercial. mRESVIA entered an RSV market already served by two larger competitors, and 2025 sales were only $8 million. mCOMBRIAX may face the same problem if doctors and pharmacies stick with separate flu and COVID shots.

We watchTrack mRESVIA and mCOMBRIAX product sales during each respiratory season.

Losses drain the cash runway

High impact · Medium odds

Moderna is cutting costs, but the company is still losing a lot of money. Q1 2026 net loss was $1.3 billion, and the $950 million settlement payment is due in Q3 2026. If revenue growth stalls, cost cuts may not be enough.

We watchWatch quarterly net loss, adjusted cash costs, and cash after the Q3 2026 settlement payment.

The pipeline misses again

High impact · Medium odds

The CMV vaccine failed its Phase 3 congenital CMV trial in 2025, which raised the risk that the platform may not work equally well in every disease area. The remaining late-stage bets now carry more weight. A miss in flu, melanoma, or rare disease would hurt the bull case.

We watchWatch the August 5, 2026 mRNA-1010 FDA decision and 2026 data for mRNA-4157 and mRNA-3927.

Regulators slow the combo strategy

Medium impact · Medium odds

mCOMBRIAX is approved in Europe, but the U.S. path is still not settled. Moderna is waiting for FDA guidance on a potential re-filing for the flu and COVID combo vaccine. A delay would push out one of the clearest ways to rebuild respiratory revenue.

We watchWatch FDA feedback on the mRNA-1083 U.S. filing plan.

Pricing rules cut vaccine revenue

Medium impact · Medium odds

Moderna warned that U.S. drug pricing reforms, including most-favored-nation models, could hurt revenue. These models can tie U.S. prices to lower prices in other countries. That matters because the U.S. is often a key profit pool for vaccines and biotech drugs.

We watchWatch U.S. drug pricing proposals that include vaccine products or international price links.
06 Quick answers

In one breath

What does Moderna actually sell now?

Moderna sells COVID vaccines, an RSV vaccine, and a flu plus COVID combo vaccine approved in Europe. COVID vaccines still make up nearly all product sales based on 2025 results.

Why is Moderna still losing money?

COVID demand is much lower than during the pandemic, while Moderna still spends heavily on research, trials, manufacturing, and launches. Q1 2026 also included a $950 million litigation settlement charge.

What is Moderna's biggest upcoming catalyst?

The clearest near-term catalyst is the FDA decision for mRNA-1010, the seasonal flu vaccine, by August 5, 2026. Investors will also watch mCOMBRIAX uptake in Europe and data from cancer and rare disease programs.

Is Moderna only a COVID company?

No, but it still depends heavily on COVID vaccine sales today. The investment case is about whether flu, RSV, combo vaccines, cancer therapy, and rare disease programs can create the next revenue base.